



Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 2/21/2013 EST.

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

Appendix B: Acronyms (Last updated November 1, 2012; last reviewed November 1, 2012)

3TC	lamivudine
AAP	American Academy of Pediatrics
ABC	abacavir
ALT	alanine aminotransferase
ANC	absolute neutrophil count
ART	antiretroviral therapy antiretroviral treatment
ARV	antiretroviral
AST	aspartate aminotransferase
ATV	atazanavir
ATV/r	atazanavir/ritonavir
AUC	area under the curve
AV	atrioventricular
BMD	bone mineral density
BMI	body mass index
BUN	blood urea nitrogen
cART	combination antiretroviral therapy
CBC	complete blood count
CDC	Centers for Disease Control and Prevention
CHER Trial	The Children with HIV Early Antiretroviral Therapy Trial
CHIPS	Collaborative HIV Pediatric Study
CK	creatinine kinase
C _{max}	maximum plasma concentration
C _{min}	minimum plasma concentration
CMV	cytomegalovirus
CNS	central nervous system
COBI	cobicistat
CPK	creatinine phosphokinase
CrCl	creatinine clearance
CT	computed tomography continuous therapy
CVD	cardiovascular disease
CYP	cytochrome P

d4T	stavudine
ddI	didanosine
DM	diabetes mellitus
D/M	dual-mixed (tropic)
DMPA	depot medroxyprogesterone acetate
DOT	directly observed therapy
DRESS	drug rash with eosinophilia and systemic symptoms
DRV	darunavir
DXA	dual-energy x-ray absorptiometry
EBV	Epstein-Barr virus
EC	enteric-coated
ECG	electrocardiogram
EFV	efavirenz
ELISA	enzyme-linked immunosorbent assay
EM	erythema multiforme
ENV	enfuvirtide
ETR	etravirine
EVG	elvitegravir
FDA	Food and Drug Administration
FPG	fasting plasma glucose
FPV	fosamprenavir
FTC	emtricitabine
FXB	François-Xavier Bagnoud Center
G6PD	glucose-6-phosphate dehydrogenase
G-CSF	granulocyte colony-stimulating factor
GGT	gamma glutamyl transpeptidase
GI	gastrointestinal
GIQ	genotypic inhibitory quotient
HAART	highly active antiretroviral therapy
HAV	hepatitis A virus
HBV	hepatitis B virus
HCV	hepatitis C virus
HDL	high-density lipoprotein
HDL-C	high-density lipoprotein cholesterol

Hgb	hemoglobin
HHS	U.S. Department of Health and Human Services
HIVMA	HIV Medicine Association
HPPMCS	HIV Paediatric Prognostic Markers Collaborative Study
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
HSV	herpes simplex virus
IAS-USA	International Antiviral Society-USA
IC ₅₀	mean inhibitory concentration
ICH	intracranial hemorrhage
IDSA	Infectious Diseases Society of America
IDV	indinavir
IFA assay	immunofluorescent antibody assay
IgE	immunoglobulin E
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IRIS	immune reconstitution inflammatory syndrome
IU	international units
IUD	intrauterine device
IV	intravenous/intravenously
IVIG	intravenous immune globulin
LDL	low-density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LFT	liver function test
LIP	lymphoid interstitial pneumonia
LPV	lopinavir
LPV/r	lopinavir/ritonavir
MAC	<i>Mycobacterium avium</i> complex
m-DOT	modified directly observed therapy
MEMS	Medication Event Monitoring System
MRI	magnetic resonance imaging
msec	milliseconds
MTCT	mother-to-child transmission
MVC	maraviroc

NA-ACCORD	North American AIDS Cohort Collaboration on Research and Design
NFV	nelfinavir
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NVP	nevirapine
OARAC	Office of AIDS Research Advisory Council
OBR	optimized background regimen
OBT	optimized background therapy
OGTT	oral glucose tolerance test
OI	opportunistic infection
PBMC	peripheral blood mononuclear cells
PCP	<i>Pneumocystis jiroveci</i> pneumonia
PCR	polymerase chain reaction
PENTA	Paediatric European Network for Treatment of AIDS
PG	plasma glucose
Pgp	p-glycoprotein
PI	protease inhibitor
PIDS	Pediatric Infectious Diseases Society
PK	pharmacokinetic
PMTCT	prevention of mother-to-child transmission
PPI	proton-pump inhibitor
PR	protease
PUFA	polyunsaturated fatty acid
RAL	raltegravir
RBV	ribavirin
RPG	random plasma glucose
RPV	rilpivirine
RT	reverse transcriptase
RTV	ritonavir
SJS	Stevens-Johnson syndrome
SQ	subcutaneous
SQV	saquinavir

STI	structured treatment interruptions
T-20	enfuvirtide
TB	tuberculosis
TC	total cholesterol
TDF	tenofovir disoproxil fumarate
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrolysis
TG	triglyceride
THAM	tris-hydroxymethyl-aminomethane
TMP-SMX	trimethoprim sulfamethoxazole
TPV	tipranavir
TPV/r	tipranavir/ritonavir
UA	urinalysis
UGT1A1	uridine diphosphate glucuronosyltransferase
ULN	upper limit of normal
USPHS	U.S. Public Health Service
WHO	World Health Organization
ZDV	zidovudine